Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06816459 · ClinicalTrials.gov registry record · Early Phase 1
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
A Early Phase 1 study of Cigarette Smoking-Related Carcinoma, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06816459: Recruiting Early Phase 1 study of Cigarette Smoking-Related Carcinoma, sponsored by Roswell Park Cancer Institute.
NCT06816459 is a Early Phase 1 study of Cigarette Smoking-Related Carcinoma that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 30 participants, below the 466-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06816459, a Early Phase 1 study of Cigarette Smoking-Related Carcinoma, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests how well current daily smoking adults can identify flavors of cigarettes. Menthol cigarettes account for 31 percent of cigarettes sold in the United States. Flavors such as menthol play an important role in the start and continued use of tobacco products. Two ways users experience flavor is through smell and taste. Menthol has cooling and numbing properties that can increase perceptions of smoothness and reduce the perceived harshness of smoke. Menthol adds a taste and aroma commonly described as "minty". The effect of menthol flavoring on smoking behavior has been studied. Use of menthol cigarettes has been associated with greater nicotine dependence and is associated with both fewer quit attempts and lower odds of quit success. In 2022, the Food and Drug Administration proposed to restrict the use of menthol as a flavor in cigarettes. Menthol has already been banned in Canada, the United Kingdom and the European Union. In late 2022, a restriction on all flavored tobacco products went into effect in California (CA), prompting the tobacco industry to introduce substitute products that did not contain menthol. It is important to find out whether New York (NY) adult smokers who smoke menthol cigarettes can identify and characterize flavors in the same cigarette brand as sold in NY versus CA following the ban of menthol cigarettes in 2022.
Primary Outcome
Will evaluate ratings of menthol smell presence (0-5 scale). Data will be analyzed under the generalized linear model approach, a flexible regression-based approach that allows for different distributional assumptions of the dependent variable, and for different link functions to describe the relationship between the independent and dependent variable. These models utilize maximum likelihood (iteratively reweighted least squares) estimation. The generalized estimating equation extension allows f
Conditions Studied
Interventions
- OTHER Cigarette smell test
- OTHER Cigarette Taste Test
- OTHER Study questionnaires
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2026-02-28 |
| Phase | Early Phase 1 |
What NCT06816459 shows while recruiting
NCT06816459 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 466-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cigarette smell test is the first listed.
NCT06816459 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06816459 about?
NCT06816459 is a clinical study titled "Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults". This clinical trial tests how well current daily smoking adults can identify flavors of cigarettes. Menthol cigarettes account for 31 percent of cigarettes sold in the United States. Flavors such as menthol play an important role in the start and continued use of tobacco products. Two ways users exp...
What is the current status of trial NCT06816459?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-10-14. Estimated completion is 2026-02-28.
What conditions does trial NCT06816459 study?
This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma.
What interventions are being tested in trial NCT06816459?
The interventions under investigation include: Cigarette smell test (OTHER), Cigarette Taste Test (OTHER), Study questionnaires (OTHER).
Who is sponsoring clinical trial NCT06816459?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06816459 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06816459's enrollment target sits among peer trials
30 20th of 21 higher than 1 of 21 other Cigarette Smoking-Related Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cigarette Smoking-Related Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
RECRUITING · NA
-
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
RECRUITING
-
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
RECRUITING · Phase 4
-
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
RECRUITING · Phase 2
-
CONNECTing to LungCare
RECRUITING · NA
-
Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI